Ignite Creation Date:
2024-05-06 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 12:27 PM
Study NCT ID:
NCT03211611
Status:
COMPLETED
Last Update Posted:
2018-05-07
First Post:
2017-07-06
Brief Title:
Management of Women With BRCA12 Mutation
Sponsor:
University Hospital Montpellier
Organization:
University Hospital Montpellier
Study Overview
Official Title:
Role of General Practionners in Management of Women With BRCA12 Mutation
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to determine general practitionners role in management of women with BRCA12 mutation
This study will be conduct between April 2017 and December 2017 at Montpellier University Hospital on women followed-up in the department of genetics and their general practitionners GP Patients and their GP will be called by the investigators and questionnaire will be given to them Questionnaire includes questions for patients and their GP The primary endpoint was to determine the rate of GP having sufficient knowledge of the adequate management of patients with BRCA1 2 mutation Adequate knowledge includes systematic search for a family history of cancer knowing criteria required to refer women in oncogenetic department and the ability to respond to patients questions Secondary endpoint was to determine women opinion on their GP whether or not well managed for their BRCA 1 2 mutation
This study will be conduct between April 2017 and December 2017 at Montpellier University Hospital on women followed-up in the department of genetics and their general practitionners GP Patients and their GP will be called by the investigators and questionnaire will be given to them Questionnaire includes questions for patients and their GP The primary endpoint was to determine the rate of GP having sufficient knowledge of the adequate management of patients with BRCA1 2 mutation Adequate knowledge includes systematic search for a family history of cancer knowing criteria required to refer women in oncogenetic department and the ability to respond to patients questions Secondary endpoint was to determine women opinion on their GP whether or not well managed for their BRCA 1 2 mutation
Detailed Description:
PURPOSE The aim of this study is to determine general practitionners role in management of women with BRCA12 mutation
METHODS
This study will be conduct between April 2017 and December 2017 at Montpellier University Hospital on women followed-up in the department of genetics and their general practitionners GP Patients and their GP will be called by the investigators and questionnaire will be given to them Questionnaire includes questions for patients and their GP The primary endpoint was to determine the rate of GP having sufficient knowledge of the adequate management of patients with BRCA1 2 mutation Adequate knowledge includes systematic search for a family history of cancer knowing criteria required to refer women in oncogenetic department and the ability to respond to patients questions Secondary endpoint was to determine women opinion on their GP whether or not well managed for their BRCA 1 2 mutation
METHODS
This study will be conduct between April 2017 and December 2017 at Montpellier University Hospital on women followed-up in the department of genetics and their general practitionners GP Patients and their GP will be called by the investigators and questionnaire will be given to them Questionnaire includes questions for patients and their GP The primary endpoint was to determine the rate of GP having sufficient knowledge of the adequate management of patients with BRCA1 2 mutation Adequate knowledge includes systematic search for a family history of cancer knowing criteria required to refer women in oncogenetic department and the ability to respond to patients questions Secondary endpoint was to determine women opinion on their GP whether or not well managed for their BRCA 1 2 mutation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None